临床试验/NCT05128201

NCT05128201招募中2 期

Consolidative Radiotherapy Combined With Camrelizumab and Chemotherapy for Oligometastatic Nasopharyngeal Carcinoma: A Multicenter, Open-Label, Phase II Trial (NPC-CR01)

Jiangxi Provincial Cancer Hospital3 个研究点分布在 1 个国家目标入组 63 人开始时间: 2021年12月1日最近更新: 2024年4月30日

适应症

试验速览

阶段: 2 期
状态: 招募中
发起方
入组人数: 63
试验地点: 3
主要终点: Progression-free survival

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The purpose of this study is to explore the efficacy and tolerance of local consolidative radiotherapy combined with Camrelizumab and chemotherapy in patients with oligometastatic nasopharyngeal carcinoma

详细描述

This trial was a single-arm, multicenter phase Ⅱ clinical study. Eligible oligometastatic NPC patients were scheduled to evaluate the efficacy and tolerance of local consolidative radiotherapy combined with camrelizumab and chemotherapy in patients with oligometastatic NPC. Progression-free survival (PFS) determined will be the primary outcome measures.

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 70 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•1. 18-70 years old, no gender limit;
•2. Oligo metastasis is defined as less than or equal to 5 metastatic lesions and less than or equal to 2 metastatic organs
•3. Patients with an ECOG score of 0 or 1, and an expected survival period of ≥6 months;
•4. Has good organ function:
•Hematology: WBC>3.0×109/L; ANC>1.5×109/L; Hb>90g/L; PLT>100×109/L; Albumin ≥3g/dL;
•Liver function: bilirubin ≤ 1.5 times the upper limit of normal (ULN) (patients with known Gilbert disease and serum bilirubin level ≤ 3 times ULN can be included), AST and ALT ≤ 3 times ULN (if liver metastases occur , Then AST/ALT≤5 times ULN), and alkaline phosphatase≤3 times ULN (if liver or bone metastasis occurs, ALP≤5 times ULN); （3） Coagulation function: International normalized ratio (INR) or prothrombin time (PT) or activated partial thromboplastin time (APTT) ≤ 1.5 times ULN; （4）Renal function: According to the Cockcroft-Gault formula (Appendix 8), serum creatinine ≤1.5 times ULN or creatinine clearance ≥60mL/min.
•5. Female subjects have a negative pregnancy test (for female patients with fertility); female patients without fertility;
•6. Male patients with fertility and female patients with fertility and risk of pregnancy must agree to take adequate contraceptive measures throughout the study period, and contraception lasts for 12 months after receiving this program.
•7. Patients who are willing and able to comply with visit arrangements, treatment plans, laboratory tests and other research procedures;
•8. During the research period, they are willing to comply with the arrangement and cannot participate in any other clinical research on drugs and medical devices;
•9. For patients who have previously received neoadjuvant chemotherapy, adjuvant chemotherapy, radiotherapy or radiotherapy for non-metastatic diseases, the time from the last chemotherapy and/or radiotherapy to randomization must reach a non-treatment interval of ≥ 6 months . Oral S1 and capecitabine have no requirement for treatment interval for those who are progressing during chemotherapy.
•10. The patients sign a formal informed consent form to show that they understand that this study complies with the hospital's policies

排除标准

•1. Those who have a history of severe immediate hypersensitivity to any of the drugs used in this study;
•2. Suffered from other malignant tumors other than nasopharyngeal carcinoma within 5 years (except for tumors with an expected 5-year OS>90%, such as non-melanoma skin cancer or pre-invasive cervical cancer);
•3. Any of the following conditions in the 6 months before screening: myocardial infarction, severe/unstable angina, coronary artery/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, transient cerebral ischemia Onset or symptomatic pulmonary embolism. Patients with known coronary artery disease, congestive heart failure that does not meet the above criteria, or left ventricular ejection fraction <50% must adopt an optimized and stable medical plan determined by the treating doctor. If appropriate, you can consult a cardiologist;
•4. Have received any of the following treatments:
•Have received anti-PD-1 or anti-PD-L1 antibody therapy in the past;
•Have received any investigational drug within 4 weeks before using the investigational drug for the first time;
•A large number of glucocorticoids or other immunosuppressants (including but not limited to prednisone, dexamethasone, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor) have been used in the 4 weeks before treatment Subjects with anti-TNF drugs, or subjects in need of hormone therapy during clinical trials. Other special circumstances require communication with the sponsor. In the absence of active autoimmune diseases, inhaled or topical steroids and adrenal cortex hormones with a dose> 10 mg/day of prednisone are allowed to be substituted;
•Those who have been vaccinated with anti-tumor vaccines or the study drug has been vaccinated with live vaccines within 4 weeks before the first administration;
•Have undergone major surgery or severe trauma within 4 weeks before using the study drug for the first time;
•Enroll in another clinical study at the same time, unless it is an observational (non-interventional) clinical study or an interventional clinical study follow-up;
•5. Patients with active autoimmune disease or a history of autoimmune disease but may relapse. Remarks: Patients with the following diseases are not excluded and can enter further screening:
•Controlled type 1 diabetes
•Hypothyroidism (if only hormone replacement therapy can be used to control)
•Skin diseases that do not require systemic treatment (such as vitiligo, psoriasis, hair loss)
•Any other diseases that are not expected to recur without external triggers
•6. Active infections, including tuberculosis, hepatitis B, hepatitis C and human immunodeficiency virus. Patients with positive HBV surface antigen (HBsAg) but HBV DNA <1000 copies/mL are eligible to participate in this study; patients with positive HCV antibody test results are only allowed if the HCV RNA polymerase chain reaction test results are negative. Be selected for this study;
•7. Idiopathic pulmonary fibrosis, drug-induced pneumonia, organizing pneumonia (bronchiolitis obliterans), idiopathic pneumonia, or chest CT scan at the time of screening shows evidence of active pneumonia;
•8. Drug abuse or alcohol addiction;
•9. No capacity for civil conduct or limited capacity for civil conduct;
•10. The patient has a physical or mental illness, and the researcher believes that the patient cannot fully or fully understand the possible complications of this study;
•11. Other serious acute or chronic medical conditions (including immune colitis, inflammatory diseases, Enteropathy, non-infectious pneumonia, pulmonary fibrosis) or mental illness (including dementia and epilepsy, recent, past year or active suicidal ideation or behavior) or abnormal laboratory tests;
•12. Patients whose expected survival time is less than 6 months;
•13. Patients with significantly reduced heart, liver, lung, kidney and bone marrow functions
•14. Previously diagnosed as immunodeficiency or known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related diseases;
•15. Female patients during pregnancy or lactation, male or female patients who are fertile but are unwilling or unable to use contraception during the entire study period and at least one year after the end of the treatment plan;

结局指标

主要结局

Progression-free survival

时间窗: 2 years

The time from the start of treatment to the first observation of disease progression or death from any cause (whichever occurs first)

次要结局

Disease control rate (DCR)(2 years)
Objective response rate (ORR)(2 years)
Duration of Overall Response (DOR)(2 years)
Overall survival (OS)(3 years)

研究者

发起方

Jiangxi Provincial Cancer Hospital

申办方类型

Other

责任方

Sponsor

研究点 (3)

Loading locations...

相似试验

Unknown

不适用

Chemotherapy Combination With Local Radiotherapy and rhGM-CSF for Oligometastatic Stage IV NSCLC PatientsCarcinoma, Non-Small-Cell Lung

NCT03489616Shandong Cancer Hospital and Institute45

招募中

不适用

Radiotherapy Strategies for Use in Combined Treatment of Small-cell Lung CancerSmall Cell Lung Carcinoma

NCT06529081Copernicus Memorial Hospital165

招募中

2 期

Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal CarcinomaOligometastasisRadiotherapyNasopharyngeal Carcinoma

NCT04221516Nanfang Hospital, Southern Medical University52

Unknown

不适用

Combination of Hyperfractionated Radiotherapy With Immunotherapy in Massive TumorsImmunotherapySBRTBulky Tumor

NCT04587817Peking University First Hospital60

进行中（未招募）

3 期

NCT04248452ECOG-ACRIN Cancer Research Group314